A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2002
11/07/2002	WO2001047866A9 Substituted 1 and 2 naphthol mannich bases
11/07/2002	WO2001034586A3 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
11/07/2002	WO2000064420A3 Compositions and methods for treating amyloidosis using sulphonate derivatives
11/07/2002	US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002	US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002	US20020165374 Secreted protein HFEAF41
11/07/2002	US20020165343 Growth hormone secretagogues
11/07/2002	US20020165342 Glucagon-like insulinotropic peptides, compositions and methods
11/07/2002	US20020165285 Production of dry powders of one or more oxygenated carotenoids
11/07/2002	US20020165282 PPAR agonists
11/07/2002	US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002	US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002	US20020165252 Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation
11/07/2002	US20020165247 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
11/07/2002	US20020165234 Selective B3 adrenergic agonists
11/07/2002	US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002	US20020165228 Antiproliferative agents; antidiabetic agents
11/07/2002	US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002	US20020165217 Combination treatment for anxiety and depression
11/07/2002	US20020165216 Controlling oxidation stresses
11/07/2002	US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002	US20020165197 Administering adenosine receptor ligand
11/07/2002	US20020165164 New effectors of dipeptidyl peptidase IV for topical use
11/07/2002	US20020165155 Crystallization of IGF-1
11/07/2002	US20020165154 Lipoprotein-regulating medicaments
11/07/2002	US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002	US20020164773 Generation of extracellular, polysaccharides of basidiomycetes mushrooms; obtain fungi, propagate in nutrient broths, isolating biomass from culture by precipitation
11/07/2002	US20020164758 Enzymatic polypeptide for use in the diagnosis and treatment of allergies, heart and respiratory disorders
11/07/2002	US20020164734 Human pelota homolog
11/07/2002	US20020164719 Targeting pharmaceutical agents to injured tissues
11/07/2002	US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002	US20020164600 PD-L2 molecules: novel PD-1 ligands and uses therefor
11/07/2002	US20020164387 Herbal composition and method for controlling body weight and composition
11/07/2002	US20020164355 Test to detect antibodies; calibration
11/07/2002	US20020164352 Dietetics; anticholesterol agents; antidiabetic agents
11/07/2002	US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002	US20020164329 Adsorption and removal of endotoxin from physiological fluids using cationic helix peptides
11/07/2002	US20020164267 Preventing immunologically mediated beta cell failure prior to or after the onset of Type 2 diabetes with inhaled insulin, by administering to a human patient in need of such prevention, an effective amount of inhaled insulin
11/07/2002	CA2672001A1 N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2445963A1 Polymethoxylated flavones for treating insulin resistance
11/07/2002	CA2445871A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445859A1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
11/07/2002	CA2445843A1 The use of enantiomeric pure escitalopram
11/07/2002	CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	CA2445583A1 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7h-[1,4]dioxino[2,3-e]indole
11/07/2002	CA2445581A1 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445552A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta[a]naphthalene
11/07/2002	CA2445543A1 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-¬1,4\|-benzodioxans
11/07/2002	CA2445376A1 Substance rkb-3564 having angiogenesis inhibitory action
11/07/2002	CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002	CA2445343A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2444911A1 Fusion molecules and methods for treatment of immune diseases
11/07/2002	CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2444429A1 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	CA2443625A1 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
11/07/2002	CA2440775A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
11/07/2002	CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002	EP1254668A2 Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
11/06/2002	EP1254662A2 Methods and kits for treating depression or preventing deterioration of cognitive function
11/06/2002	EP1254270A1 Methods and materials relating to cub domain polypeptides and polynucleotides
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254259A1 Antisense modulation of pepck-cytosolic expression
11/06/2002	EP1254251A2 Neurosteroids as markers for alzheimer's disease
11/06/2002	EP1254238A2 Novel elongase gene and method for producing multiple-unsaturated fatty acids
11/06/2002	EP1254236A2 Drug metabolizing enzymes
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254231A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom
11/06/2002	EP1254224A2 Interferon-alpha induced genes
11/06/2002	EP1254222A1 Human gaba receptor proteins and polynucleotides encoding the same
11/06/2002	EP1254214A2 Human protein kinases and protein kinase-like enzymes
11/06/2002	EP1254212A2 Methods of preparing and using a viral vector library
11/06/2002	EP1254209A2 Bioavailable composition of natural and synthetic hca
11/06/2002	EP1254139A1 4-heteroaryl-1,4-diazabicyclo 3.2.2]nonane, preparation and therapeutic use thereof
11/06/2002	EP1254138A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
11/06/2002	EP1254134A2 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
11/06/2002	EP1254132A1 Food product and process
11/06/2002	EP1254124A1 Dipeptide nitrile cathpsin k inhibitors
11/06/2002	EP1254123A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
11/06/2002	EP1254118A2 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
11/06/2002	EP1254114A2 Melanocortin receptor agonists and antagonists
11/06/2002	EP1254113A1 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
11/06/2002	EP1254111A1 Novel vitamin d analogues
11/06/2002	EP1254106A1 Calcilytic compounds
11/06/2002	EP1254102A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
11/06/2002	EP1254101A1 Propionic acid derivatives and their use in the treatment of diabetes and obesity
11/06/2002	EP1253944A2 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent
11/06/2002	EP1253926A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
11/06/2002	EP1253925A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
11/06/2002	EP1253922A2 Statin-type bone growth stimulators
11/06/2002	EP1253917A2 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
11/06/2002	EP1253915A1 Method for treating stress with a precursor of serotonin

1 ... 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 ... 1298